Drug Profile
Research programme: therapeutics for essential hypertension - Hypogen
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Hypogen
- Class
- Mechanism of Action Sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Essential hypertension
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Essential hypertension in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Essential-hypertension in USA
- 06 Jul 2016 Research programme: therapeutics for essential hypertension - Hypogen is available for licensing as of 06 Jul 2016. http://hypogen.com